[1] KUNIKO HONE. Selectivity of the imidazoline α-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned α1-adrenoceptor subtypes[J]. British Journal of Pharmacology, 1995, 116 1: 1611-1618. DOI:
10.1111/j.1476-5381.1995.tb16381.x[2] ROBERT R. RUFFOLO JR. JAMES E W. RECEPTOR INTERACTIONS OF IMIDAZOLINES: α-ADRENOCEPTORS OF RAT AND RABBIT AORTAE DIFFERENTIATED BY RELATIVE POTENCIES, AFFINITIES AND EFFICACIES OF IMIDAZOLINE AGONISTS[J]. British Journal of Pharmacology, 1982, 77 1: 169-176. DOI:
10.1111/j.1476-5381.1982.tb09283.x[3] P BOUSQUET J S J Feldman. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines.[J]. Journal of Pharmacology and Experimental Therapeutics, 1984, 230 1: 232-236.
[4] VAN A DOZE. Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity.[J]. Molecular Pharmacology, 2011, 80 4: 747-758. DOI:
10.1124/mol.111.073734[5] A.F.T. ARNSTEN J. D J. The Alpha-1 Adrenergic Agonist, Cirazoline, Impairs Spatial Working Memory Performance in Aged Monkeys[J]. Pharmacology Biochemistry and Behavior, 1997, 58 1: Pages 55-59. DOI:
10.1016/s0091-3057(96)00477-7